Galecto, Inc.
Status: Publicly traded
Direct answer
Galecto, Inc. is publicly traded on NASDAQ under the ticker DMRA.
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård...
Can you invest in Galecto, Inc.?
Yes. Galecto, Inc. trades publicly on NASDAQ as DMRA.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Galecto, Inc.
Detailed equity research is provided by MarketSnap.